We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Researchers Suggest Neurodegenerative Diseases May Spread through Nanotubes

By LabMedica International staff writers
Posted on 08 Sep 2016
A team of French neurological disease researchers has uncovered a mechanism that may explain how neurodegenerative diseases like Parkinson's disease spread inside the brain.

Investigators at Institut Pasteur (Paris, France) described the movement of alpha-synuclein aggregates from damaged neurons to undamaged neurons through novel structures called tunneling nanotubes (TNTs) that connect cells within the brain.

Classically considered an unstructured soluble protein, wild-type alpha-synuclein forms a stably folded tetramer that resists aggregation. More...
Nevertheless, alpha-synuclein aggregates to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. These disorders are known as synucleinopathies.

The investigators reported in the August 22, 2016, online edition of The EMBO Journal that using quantitative fluorescence microscopy with co-cultured neurons, they had found that alpha-synuclein fibrils efficiently transferred from donor to acceptor cells through TNTs inside lysosomal vesicles. Following transfer through TNTs, alpha-synuclein fibrils were able to seed soluble alpha-synuclein aggregation in the cytosol of acceptor cells.

The investigators proposed that donor cells with lysosomes overloaded with alpha-synuclein aggregates disposed of this material by hijacking TNT-mediated intercellular trafficking. These findings revealed a possible novel role of TNTs and lysosomes in the progression of synucleinopathies.

Related Links:
Institut Pasteur


New
Gold Member
Aspiration System
VACUSAFE
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.